Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer in vitro model

Nanomedicine
Víctor López-DávilaMarilena Loizidou

Abstract

In this work, we use cationic organic nanocarriers as chemotherapy delivery platforms and test them in a colorectal cancer 3D in vitro model. We used 3beta-(N-[N',N'-dimethylaminoethane]carbamoyl])cholesterol (DC-chol) and dioleoylphosphatidylethanolamine (DOPE) liposomes and N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) micelles, to deliver AZD6244, a MEK inhibitor, to HCT116 cells cultured as monolayers and in 3D in vitro cancer models (tumoroids). Nanoparticle-mediated drug delivery was superior to the free drug in monolayer experiments and despite their therapeutic effect being hindered by poor diffusion through the cancer mass, GCPQ micelles were also superior in tumoroids. These results support the role of nanoparticles in improving drug delivery and highlight the need to include 3D cancer models in early phases of drug development.

References

Jun 6, 1998·International Journal of Experimental Pathology·L A Kunz-SchughartR Knuechel
Jul 11, 2000·Pharmaceutical Research·S DokkaY Rojanasakul
Apr 12, 2003·FEBS Letters·Barry Halliwell
Nov 19, 2004·Nature·Neil A BhowmickHarold L Moses
Jul 25, 2006·Nature Reviews. Cancer·Andrew I Minchinton, Ian F Tannock
Aug 18, 2006·Nature Reviews. Drug Discovery·Norman E Sharpless, Ronald A Depinho
Aug 28, 2007·Cell·Kenneth M Yamada, Edna Cukierman
Sep 11, 2007·Advanced Drug Delivery Reviews·Sangmyung Rhee, Frederick Grinnell
Sep 27, 2007·Journal of the National Cancer Institute·Olivier TrédanIan F Tannock
Feb 13, 2009·Current Opinion in Genetics & Development·Arne Ostman, Martin Augsten
Apr 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Sudipta BasuShiladitya Sengupta
Jan 15, 2010·Methods in Molecular Biology·M R Mozafari
Feb 9, 2010·Tissue Engineering. Part a·Shalu Suri, Christine E Schmidt
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Apr 3, 2012·Current Opinion in Pharmacology·Víctor López-DávilaMarilena Loizidou
Sep 15, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Federico PercheVladimir P Torchilin
Nov 6, 2012·Biological & Pharmaceutical Bulletin·Motoki HinoRyuichi Ueoka
Apr 30, 2013·Acta Biomaterialia·Agata NygaUmber Cheema
Oct 12, 2013·Biotechnology Advances·Shutao Guo, Leaf Huang
Jul 31, 2014·Journal of Translational Medicine·Emilia CaputoPaolo Antonio Ascierto
Aug 6, 2014·Journal of Pharmaceutical Sciences·Ana CasadóMargarita Mora
Nov 11, 2014·Journal of Tissue Engineering·Tarig MagdeldinMarilena Loizidou
Nov 12, 2014·Expert Opinion on Investigational Drugs·Kristen Keon Ciombor, Tanios Bekaii-Saab

❮ Previous
Next ❯

Methods Mentioned

BETA
DNA assay
reversed-phase chromatography
protein assay
xenografts

Software Mentioned

Image J
GraphPad Prism5

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.